Digitisation | August 04, 2022
Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery
The WAVEsystem with the WAVEcontrol 4.0 embedded
The WAVEsystem with the WAVEcontrol 4.0 embedded
The company is focused on therapies such as skinceuticals, gastroenterology, neuropsychiatry, cardiac diabetes care etc.
Advancing to IND-enabling studies with multiple drug candidates
Supports development and commercialization of complex oral drugs using sensitive molecules, including biologicals
Syngene's collaboration with Zoetis started in 2011
Athos will perform multi-omic molecular and genetic analyses using biopsies from archived and de-identified Lahey IBD patient samples
Granite Bio's lead candidate is a novel monoclonal antibody for treatment of autoimmune and certain cancer indications. B
The addition of Sitaglyn and Siglyn to our diabetes portfolio will give patients access to a world-class oral therapy to help people manage their diabetes
These medicines have low risk of hypoglycemia, provide beta cell protection, offer cardio-renal benefits and are safe for patients with kidney or liver conditions and senior citizens
This multicenter, open-label Phase I study is designed to assess the safety and tolerability
Subscribe To Our Newsletter & Stay Updated
